S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

Hookipa Pharma Stock Price, News & Analysis (NASDAQ:HOOK)

$0.57
+0.01 (+1.77%)
(As of 12/1/2023 ET)
Compare
Today's Range
$0.55
$0.60
50-Day Range
$0.42
$0.63
52-Week Range
$0.41
$2.05
Volume
327,804 shs
Average Volume
651,893 shs
Market Capitalization
$48.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.83

Hookipa Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
914.5% Upside
$5.83 Price Target
Short Interest
Healthy
0.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.02) to ($0.97) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

180th out of 951 stocks

Pharmaceutical Preparations Industry

71st out of 436 stocks


HOOK stock logo

About Hookipa Pharma Stock (NASDAQ:HOOK)

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

HOOK Stock Price History

HOOK Stock News Headlines

HOOKIPA Pharma: HB-500 IND Application Gets FDA Clearance To Treat HIV
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Analyst Ratings for HOOKIPA Pharma
RBC Capital Keeps Their Buy Rating on Hookipa Pharma (HOOK)
HOOKIPA Announces Executive Leadership Change
RBC Capital Reaffirms Their Buy Rating on Hookipa Pharma (HOOK)
See More Headlines
Receive HOOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/20/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HOOK
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.83
High Stock Price Target
$7.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+914.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-64,920,000.00
Net Margins
-336.12%
Pretax Margin
-334.01%

Debt

Sales & Book Value

Annual Sales
$14.25 million
Book Value
$1.13 per share

Miscellaneous

Free Float
79,064,000
Market Cap
$48.27 million
Optionable
Not Optionable
Beta
0.89
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report














HOOK Stock Analysis - Frequently Asked Questions

Should I buy or sell Hookipa Pharma stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HOOK shares.
View HOOK analyst ratings
or view top-rated stocks.

What is Hookipa Pharma's stock price target for 2024?

3 Wall Street research analysts have issued twelve-month price targets for Hookipa Pharma's shares. Their HOOK share price targets range from $4.00 to $7.00. On average, they expect the company's share price to reach $5.83 in the next twelve months. This suggests a possible upside of 914.5% from the stock's current price.
View analysts price targets for HOOK
or view top-rated stocks among Wall Street analysts.

How have HOOK shares performed in 2023?

Hookipa Pharma's stock was trading at $0.81 on January 1st, 2023. Since then, HOOK shares have decreased by 29.0% and is now trading at $0.5750.
View the best growth stocks for 2023 here
.

When is Hookipa Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our HOOK earnings forecast
.

How were Hookipa Pharma's earnings last quarter?

Hookipa Pharma Inc (NASDAQ:HOOK) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. The firm earned $6.87 million during the quarter, compared to the consensus estimate of $3.39 million. Hookipa Pharma had a negative trailing twelve-month return on equity of 70.24% and a negative net margin of 336.12%.

What other stocks do shareholders of Hookipa Pharma own?
When did Hookipa Pharma IPO?

(HOOK) raised $100 million in an initial public offering (IPO) on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.

Who are Hookipa Pharma's major shareholders?

Hookipa Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (4.42%), FMR LLC (4.00%), Redmile Group LLC (1.27%), Group One Trading L.P. (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Igor Matushansky, Jorn Aldag, Reinhard Kandera and Sofinnova Capital Vi Fcpr.
View institutional ownership trends
.

How do I buy shares of Hookipa Pharma?

Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:HOOK) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -